English

SYNAGEVA BIOPHARMA CORP

EDGAR

GEVA Quarterly report (10-Q) · filed 2015-04-30

94 filing records in this dataset, filed from 1997-11-14 to 2015-04-30. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

927 thousand USD

2015 Q1 · USD

Exact inputs and evidence

Revenue: 927000 USD Source

Operating margin

-6,383.28%

2015 Q1 · %

Exact inputs and evidence

Operating Income: -59173000 USD Source
Revenue: 927000 USD Source

Operating cash flow

-47.4 million USD

2015 Q1 · USD

Exact inputs and evidence

Operating Cash Flow: -47443000 USD Source

Cash and cash equivalents: 98.6 million USD 2015-03-31 Source
Exact value

98577000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 37 million shares 2015-03-31 Source
Exact value

37002000 shares

Reported share-count change

12.21% · 4.03 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

32975000 shares · 2014-03-31· Source
37002000 shares · 2015-03-31· Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2015-04-30.

Financial data available through: 2014-12-31.

Coverage by financial measure

Revenue: 5 of 11 periods available· newest 2014-12-31
Operating income: 10 of 11 periods available· newest 2014-12-31
Net income: 10 of 11 periods available· newest 2014-12-31
Operating cash flow: 10 of 11 periods available· newest 2014-12-31
capital expenditure: No compatible figures in this window
Total assets: 5 of 11 periods available· newest 2014-12-31
Total liabilities: 5 of 11 periods available· newest 2014-12-31
Current assets: 5 of 11 periods available· newest 2014-12-31
Current liabilities: 5 of 11 periods available· newest 2014-12-31
Cash and cash equivalents: 6 of 11 periods available· newest 2014-12-31
long term debt: No compatible figures in this window
Shares outstanding: 4 of 11 periods available· newest 2014-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
-51.5%

Prior period

USD 13.37 million

2013-01-01 – 2013-12-31
Current period

USD 6.49 million

2014-01-01 – 2014-12-31

Exact inputs and evidence

6492000 − 13374000 = -6882000 USD

13374000 USD · 2013-01-01 – 2013-12-31
Inspect prior input Prior source
6492000 USD · 2014-01-01 – 2014-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · SYNAGEVA BIOPHARMA CORP · 2014-12-31 SYNAGEVA BIOPHARMA CORP (edgar:911326) Year-over-year change in Revenue: -6882000 USD Concept: fundies:Revenue Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T21:30:48Z Snapshot: 2e659e145b62e7937359189eff5497c5180b59e8b9c53cd0c26dcbf8ec576b9f Dimensions: Consolidated View: https://fundies.io/companies/edgar/911326?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 6492000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/911326/000119312515065709/geva-20141231.xml#1229797 Filing: 000119312515065709 Input fundies:Revenue: 13374000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/911326/000119312515065709/geva-20141231.xml#103726 Filing: 000119312515065709
The citation records this snapshot. The page link may show a newer release later.
Net income
−USD 97.2 million

Prior period

−USD 95.45 million

2013-01-01 – 2013-12-31
Current period

−USD 192.65 million

2014-01-01 – 2014-12-31

Exact inputs and evidence

-192648000 − -95450000 = -97198000 USD

-95450000 USD · 2013-01-01 – 2013-12-31
Inspect prior input Prior source
-192648000 USD · 2014-01-01 – 2014-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · SYNAGEVA BIOPHARMA CORP · 2014-12-31 SYNAGEVA BIOPHARMA CORP (edgar:911326) Year-over-year change in Net income: -97198000 USD Concept: fundies:NetIncome Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T21:30:48Z Snapshot: 2e659e145b62e7937359189eff5497c5180b59e8b9c53cd0c26dcbf8ec576b9f Dimensions: Consolidated View: https://fundies.io/companies/edgar/911326?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -192648000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/911326/000119312515065709/geva-20141231.xml#1230256 Filing: 000119312515065709 Input fundies:NetIncome: -95450000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/911326/000119312515065709/geva-20141231.xml#103924 Filing: 000119312515065709
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 75.12 million

Prior period

−USD 75 million

2013-01-01 – 2013-12-31
Current period

−USD 150.12 million

2014-01-01 – 2014-12-31

Exact inputs and evidence

-150124000 − -75002000 = -75122000 USD

-75002000 USD · 2013-01-01 – 2013-12-31
Inspect prior input Prior source
-150124000 USD · 2014-01-01 – 2014-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · SYNAGEVA BIOPHARMA CORP · 2014-12-31 SYNAGEVA BIOPHARMA CORP (edgar:911326) Year-over-year change in Operating cash flow: -75122000 USD Concept: fundies:OperatingCashFlow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T21:30:48Z Snapshot: 2e659e145b62e7937359189eff5497c5180b59e8b9c53cd0c26dcbf8ec576b9f Dimensions: Consolidated View: https://fundies.io/companies/edgar/911326?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -150124000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/911326/000119312515065709/geva-20141231.xml#417429 Filing: 000119312515065709 Input fundies:OperatingCashFlow: -75002000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/911326/000119312515065709/geva-20141231.xml#92502 Filing: 000119312515065709
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Capital expenditure.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2014 2014-01-01 – 2014-12-31

Revenue USD 6.49 million 100% of revenue
Operating costs Derived USD 198.63 million 3,060% of revenue
Operating income −USD 192.13 million −2,960% of revenue
Tax, interest and other Derived USD 515,000 7.9% of revenue
Net income −USD 192.65 million −2,967% of revenue

Cash

Operating cash flow −USD 150.12 million −2,312% of revenue
Capital expenditure Unavailable An input is unavailable.
Free cash flow Derived Unavailable An input is unavailable.

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2010 Operating loss: operating costs were 2,306% of revenue.
2011 Operating loss: operating costs were 1,292% of revenue.
2012 Operating loss: operating costs were 388% of revenue.
2013 Operating loss: operating costs were 817% of revenue.
2014 Operating loss: operating costs were 3,060% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2010 2010-01-01 – 2010-12-31	595000	13718000 Derived	-13123000	-2299000 Derived	-10824000	Unavailable	Source 2010-01-01 – 2010-12-31: 595000 USD Inspect Revenue Open source 2010-01-01 – 2010-12-31: -13123000 USD Inspect Operating Income Open source 2010-01-01 – 2010-12-31: -10824000 USD Inspect Net Income Open source 2010-01-01 – 2010-12-31: -10550000 USD Inspect Operating Cash Flow Open source
2011 2011-01-01 – 2011-12-31	2099000	27118000 Derived	-25019000	287000 Derived	-25306000	Unavailable	Source 2011-01-01 – 2011-12-31: 2099000 USD Inspect Revenue Open source 2011-01-01 – 2011-12-31: -25019000 USD Inspect Operating Income Open source 2011-01-01 – 2011-12-31: -25306000 USD Inspect Net Income Open source 2011-01-01 – 2011-12-31: -16589000 USD Inspect Operating Cash Flow Open source
2012 2012-01-01 – 2012-12-31	14954000	57975000 Derived	-43021000	-72000 Derived	-42949000	Unavailable	Source 2012-01-01 – 2012-12-31: 14954000 USD Inspect Revenue Open source 2012-01-01 – 2012-12-31: -43021000 USD Inspect Operating Income Open source 2012-01-01 – 2012-12-31: -42949000 USD Inspect Net Income Open source 2012-01-01 – 2012-12-31: -30935000 USD Inspect Operating Cash Flow Open source
2013 2013-01-01 – 2013-12-31	13374000	109277000 Derived	-95903000	-453000 Derived	-95450000	Unavailable	Source 2013-01-01 – 2013-12-31: 13374000 USD Inspect Revenue Open source 2013-01-01 – 2013-12-31: -95903000 USD Inspect Operating Income Open source 2013-01-01 – 2013-12-31: -95450000 USD Inspect Net Income Open source 2013-01-01 – 2013-12-31: -75002000 USD Inspect Operating Cash Flow Open source
2014 2014-01-01 – 2014-12-31	6492000	198625000 Derived	-192133000	515000 Derived	-192648000	Unavailable	Source 2014-01-01 – 2014-12-31: 6492000 USD Inspect Revenue Open source 2014-01-01 – 2014-12-31: -192133000 USD Inspect Operating Income Open source 2014-01-01 – 2014-12-31: -192648000 USD Inspect Net Income Open source 2014-01-01 – 2014-12-31: -150124000 USD Inspect Operating Cash Flow Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 6.5M 2014

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20102010-12-31	Revenue	595000	Revenue: 595000 Open source
20112011-12-31	Revenue	2099000	Revenue: 2099000 Open source
20122012-12-31	Revenue	14954000	Revenue: 14954000 Open source
20132013-12-31	Revenue	13374000	Revenue: 13374000 Open source
20142014-12-31	Revenue	6492000	Revenue: 6492000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-51.5% 2014

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20102010-12-31	Year over year	No prior comparable period	Revenue: 595000 Open source
20112011-12-31	Year over year	252.8%	Revenue: 2099000 Open source Revenue: 595000 Open source
20122012-12-31	Year over year	612.4%	Revenue: 14954000 Open source Revenue: 2099000 Open source
20132013-12-31	Year over year	-10.6%	Revenue: 13374000 Open source Revenue: 14954000 Open source
20142014-12-31	Year over year	-51.5%	Revenue: 6492000 Open source Revenue: 13374000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -2,959.5% 2014

Net margin -2,967.5% 2014

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20102010-12-31	Operating margin	-2,205.5%	Operating Income: -13123000 Open source Revenue: 595000 Open source
20112011-12-31	Operating margin	-1,191.9%	Operating Income: -25019000 Open source Revenue: 2099000 Open source
20122012-12-31	Operating margin	-287.7%	Operating Income: -43021000 Open source Revenue: 14954000 Open source
20132013-12-31	Operating margin	-717.1%	Operating Income: -95903000 Open source Revenue: 13374000 Open source
20142014-12-31	Operating margin	-2,959.5%	Operating Income: -192133000 Open source Revenue: 6492000 Open source
20102010-12-31	Net margin	-1,819.2%	Net Income: -10824000 Open source Revenue: 595000 Open source
20112011-12-31	Net margin	-1,205.6%	Net Income: -25306000 Open source Revenue: 2099000 Open source
20122012-12-31	Net margin	-287.2%	Net Income: -42949000 Open source Revenue: 14954000 Open source
20132013-12-31	Net margin	-713.7%	Net Income: -95450000 Open source Revenue: 13374000 Open source
20142014-12-31	Net margin	-2,967.5%	Net Income: -192648000 Open source Revenue: 6492000 Open source
20102010-12-31	Free cash flow margin	Not reported	Revenue: 595000 Open source Operating Cash Flow: -10550000 Open source
20112011-12-31	Free cash flow margin	Not reported	Revenue: 2099000 Open source Operating Cash Flow: -16589000 Open source
20122012-12-31	Free cash flow margin	Not reported	Revenue: 14954000 Open source Operating Cash Flow: -30935000 Open source
20132013-12-31	Free cash flow margin	Not reported	Revenue: 13374000 Open source Operating Cash Flow: -75002000 Open source
20142014-12-31	Free cash flow margin	Not reported	Revenue: 6492000 Open source Operating Cash Flow: -150124000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -150.1M 2014

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20102010-12-31	Operating cash flow	-10550000	Operating Cash Flow: -10550000 Open source
20112011-12-31	Operating cash flow	-16589000	Operating Cash Flow: -16589000 Open source
20122012-12-31	Operating cash flow	-30935000	Operating Cash Flow: -30935000 Open source
20132013-12-31	Operating cash flow	-75002000	Operating Cash Flow: -75002000 Open source
20142014-12-31	Operating cash flow	-150124000	Operating Cash Flow: -150124000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

Not enough comparable data to show this history.

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20102010-12-31	Free cash flow	Unavailable	Operating Cash Flow: -10550000 Open source
20112011-12-31	Free cash flow	Unavailable	Operating Cash Flow: -16589000 Open source
20122012-12-31	Free cash flow	Unavailable	Operating Cash Flow: -30935000 Open source
20132013-12-31	Free cash flow	Unavailable	Operating Cash Flow: -75002000 Open source
20142014-12-31	Free cash flow	Unavailable	Operating Cash Flow: -150124000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

6.1% 2014

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2010-12-31	Liabilities / assets	Not reported	No source recorded
20112011-12-31	Liabilities / assets	11.1%	Total Liabilities: 9250000 Open source Total Assets: 83298000 Open source
20122012-12-31	Liabilities / assets	5.4%	Total Liabilities: 13079000 Open source Total Assets: 243256000 Open source
20132013-12-31	Liabilities / assets	4%	Total Liabilities: 17748000 Open source Total Assets: 447949000 Open source
20142014-12-31	Liabilities / assets	6.1%	Total Liabilities: 30964000 Open source Total Assets: 504203000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

18.14× 2014

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
2010-12-31	Current assets / current liabilities	Not reported	No source recorded
20112011-12-31	Current assets / current liabilities	7.83×	Current Assets: 64651000 Open source Current Liabilities: 8259000 Open source
20122012-12-31	Current assets / current liabilities	17.21×	Current Assets: 225107000 Open source Current Liabilities: 13079000 Open source
20132013-12-31	Current assets / current liabilities	29.94×	Current Assets: 416723000 Open source Current Liabilities: 13920000 Open source
20142014-12-31	Current assets / current liabilities	18.14×	Current Assets: 457832000 Open source Current Liabilities: 25243000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2004 2004-01-01 – 2004-12-31	−USD 40.09 million Exact value Exact value: -40088000 USD 2004-01-01 – 2004-12-31: -40088000 USD Inspect Net Income Open source Share or cite Citation for Net Income · SYNAGEVA BIOPHARMA CORP · 2004-12-31 SYNAGEVA BIOPHARMA CORP (edgar:911326) Net Income: -40088000 USD Concept: fundies:NetIncome Period: 2004-01-01 to 2004-12-31 Values: Latest reported Published: 2026-11-02T21:30:48Z Snapshot: 2e659e145b62e7937359189eff5497c5180b59e8b9c53cd0c26dcbf8ec576b9f Dimensions: Consolidated View: https://fundies.io/companies/edgar/911326/explain?concept=fundies%3ANetIncome&period=2004-12-31&surface=latest&period_type=duration&start=2004-01-01&unit=USD&dimensions= Input fundies:NetIncome: -40088000 USD (2004-01-01 to 2004-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/911326/0001193125-07-057019.txt#11784 The citation records this snapshot. The page link may show a newer release later.	−USD 42.63 million Exact value Exact value: -42628000 USD 2004-01-01 – 2004-12-31: -42628000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SYNAGEVA BIOPHARMA CORP · 2004-12-31 SYNAGEVA BIOPHARMA CORP (edgar:911326) Operating Cash Flow: -42628000 USD Concept: fundies:OperatingCashFlow Period: 2004-01-01 to 2004-12-31 Values: Latest reported Published: 2026-11-02T21:30:48Z Snapshot: 2e659e145b62e7937359189eff5497c5180b59e8b9c53cd0c26dcbf8ec576b9f Dimensions: Consolidated View: https://fundies.io/companies/edgar/911326/explain?concept=fundies%3AOperatingCashFlow&period=2004-12-31&surface=latest&period_type=duration&start=2004-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -42628000 USD (2004-01-01 to 2004-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/911326/0001193125-07-057019.txt#12148 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2005 2005-01-01 – 2005-12-31	−USD 8.11 million Exact value Exact value: -8106000 USD 2005-01-01 – 2005-12-31: -8106000 USD Inspect Net Income Open source Share or cite Citation for Net Income · SYNAGEVA BIOPHARMA CORP · 2005-12-31 SYNAGEVA BIOPHARMA CORP (edgar:911326) Net Income: -8106000 USD Concept: fundies:NetIncome Period: 2005-01-01 to 2005-12-31 Values: Latest reported Published: 2026-11-02T21:30:48Z Snapshot: 2e659e145b62e7937359189eff5497c5180b59e8b9c53cd0c26dcbf8ec576b9f Dimensions: Consolidated View: https://fundies.io/companies/edgar/911326/explain?concept=fundies%3ANetIncome&period=2005-12-31&surface=latest&period_type=duration&start=2005-01-01&unit=USD&dimensions= Input fundies:NetIncome: -8106000 USD (2005-01-01 to 2005-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/911326/0001193125-08-059027.txt#10484 The citation records this snapshot. The page link may show a newer release later.	−USD 10.03 million Exact value Exact value: -10032000 USD 2005-01-01 – 2005-12-31: -10032000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SYNAGEVA BIOPHARMA CORP · 2005-12-31 SYNAGEVA BIOPHARMA CORP (edgar:911326) Operating Cash Flow: -10032000 USD Concept: fundies:OperatingCashFlow Period: 2005-01-01 to 2005-12-31 Values: Latest reported Published: 2026-11-02T21:30:48Z Snapshot: 2e659e145b62e7937359189eff5497c5180b59e8b9c53cd0c26dcbf8ec576b9f Dimensions: Consolidated View: https://fundies.io/companies/edgar/911326/explain?concept=fundies%3AOperatingCashFlow&period=2005-12-31&surface=latest&period_type=duration&start=2005-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -10032000 USD (2005-01-01 to 2005-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/911326/0001193125-08-059027.txt#10848 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2006 2006-01-01 – 2006-12-31	USD 7.38 million Exact value Exact value: 7384000 USD 2006-01-01 – 2006-12-31: 7384000 USD Inspect Net Income Open source Share or cite Citation for Net Income · SYNAGEVA BIOPHARMA CORP · 2006-12-31 SYNAGEVA BIOPHARMA CORP (edgar:911326) Net Income: 7384000 USD Concept: fundies:NetIncome Period: 2006-01-01 to 2006-12-31 Values: Latest reported Published: 2026-11-02T21:30:48Z Snapshot: 2e659e145b62e7937359189eff5497c5180b59e8b9c53cd0c26dcbf8ec576b9f Dimensions: Consolidated View: https://fundies.io/companies/edgar/911326/explain?concept=fundies%3ANetIncome&period=2006-12-31&surface=latest&period_type=duration&start=2006-01-01&unit=USD&dimensions= Input fundies:NetIncome: 7384000 USD (2006-01-01 to 2006-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/911326/0001193125-09-053003.txt#9824 The citation records this snapshot. The page link may show a newer release later.	USD 12.18 million Exact value Exact value: 12177000 USD 2006-01-01 – 2006-12-31: 12177000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SYNAGEVA BIOPHARMA CORP · 2006-12-31 SYNAGEVA BIOPHARMA CORP (edgar:911326) Operating Cash Flow: 12177000 USD Concept: fundies:OperatingCashFlow Period: 2006-01-01 to 2006-12-31 Values: Latest reported Published: 2026-11-02T21:30:48Z Snapshot: 2e659e145b62e7937359189eff5497c5180b59e8b9c53cd0c26dcbf8ec576b9f Dimensions: Consolidated View: https://fundies.io/companies/edgar/911326/explain?concept=fundies%3AOperatingCashFlow&period=2006-12-31&surface=latest&period_type=duration&start=2006-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 12177000 USD (2006-01-01 to 2006-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/911326/0001193125-09-053003.txt#10202 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2007 2007-01-01 – 2007-12-31	USD 27.43 million Exact value Exact value: 27425000 USD 2007-01-01 – 2007-12-31: 27425000 USD Inspect Net Income Open source Share or cite Citation for Net Income · SYNAGEVA BIOPHARMA CORP · 2007-12-31 SYNAGEVA BIOPHARMA CORP (edgar:911326) Net Income: 27425000 USD Concept: fundies:NetIncome Period: 2007-01-01 to 2007-12-31 Values: Latest reported Published: 2026-11-02T21:30:48Z Snapshot: 2e659e145b62e7937359189eff5497c5180b59e8b9c53cd0c26dcbf8ec576b9f Dimensions: Consolidated View: https://fundies.io/companies/edgar/911326/explain?concept=fundies%3ANetIncome&period=2007-12-31&surface=latest&period_type=duration&start=2007-01-01&unit=USD&dimensions= Input fundies:NetIncome: 27425000 USD (2007-01-01 to 2007-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/911326/0001193125-10-058544.txt#9126 The citation records this snapshot. The page link may show a newer release later.	USD 21.59 million Exact value Exact value: 21592000 USD 2007-01-01 – 2007-12-31: 21592000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SYNAGEVA BIOPHARMA CORP · 2007-12-31 SYNAGEVA BIOPHARMA CORP (edgar:911326) Operating Cash Flow: 21592000 USD Concept: fundies:OperatingCashFlow Period: 2007-01-01 to 2007-12-31 Values: Latest reported Published: 2026-11-02T21:30:48Z Snapshot: 2e659e145b62e7937359189eff5497c5180b59e8b9c53cd0c26dcbf8ec576b9f Dimensions: Consolidated View: https://fundies.io/companies/edgar/911326/explain?concept=fundies%3AOperatingCashFlow&period=2007-12-31&surface=latest&period_type=duration&start=2007-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 21592000 USD (2007-01-01 to 2007-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/911326/0001193125-10-058544.txt#9476 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2008 2008-01-01 – 2008-12-31	USD 8.01 million Exact value Exact value: 8009000 USD 2008-01-01 – 2008-12-31: 8009000 USD Inspect Net Income Open source Share or cite Citation for Net Income · SYNAGEVA BIOPHARMA CORP · 2008-12-31 SYNAGEVA BIOPHARMA CORP (edgar:911326) Net Income: 8009000 USD Concept: fundies:NetIncome Period: 2008-01-01 to 2008-12-31 Values: Latest reported Published: 2026-11-02T21:30:48Z Snapshot: 2e659e145b62e7937359189eff5497c5180b59e8b9c53cd0c26dcbf8ec576b9f Dimensions: Consolidated View: https://fundies.io/companies/edgar/911326/explain?concept=fundies%3ANetIncome&period=2008-12-31&surface=latest&period_type=duration&start=2008-01-01&unit=USD&dimensions= Input fundies:NetIncome: 8009000 USD (2008-01-01 to 2008-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/911326/0001193125-11-065867.txt#8717 The citation records this snapshot. The page link may show a newer release later.	USD 17.05 million Exact value Exact value: 17045000 USD 2008-01-01 – 2008-12-31: 17045000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SYNAGEVA BIOPHARMA CORP · 2008-12-31 SYNAGEVA BIOPHARMA CORP (edgar:911326) Operating Cash Flow: 17045000 USD Concept: fundies:OperatingCashFlow Period: 2008-01-01 to 2008-12-31 Values: Latest reported Published: 2026-11-02T21:30:48Z Snapshot: 2e659e145b62e7937359189eff5497c5180b59e8b9c53cd0c26dcbf8ec576b9f Dimensions: Consolidated View: https://fundies.io/companies/edgar/911326/explain?concept=fundies%3AOperatingCashFlow&period=2008-12-31&surface=latest&period_type=duration&start=2008-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 17045000 USD (2008-01-01 to 2008-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/911326/0001193125-11-065867.txt#9053 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2010 2010-01-01 – 2010-12-31	−USD 10.82 million Exact value Exact value: -10824000 USD 2010-01-01 – 2010-12-31: -10824000 USD Inspect Net Income Open source Share or cite Citation for Net Income · SYNAGEVA BIOPHARMA CORP · 2010-12-31 SYNAGEVA BIOPHARMA CORP (edgar:911326) Net Income: -10824000 USD Concept: fundies:NetIncome Period: 2010-01-01 to 2010-12-31 Values: Latest reported Published: 2026-11-02T21:30:48Z Snapshot: 2e659e145b62e7937359189eff5497c5180b59e8b9c53cd0c26dcbf8ec576b9f Dimensions: Consolidated View: https://fundies.io/companies/edgar/911326/explain?concept=fundies%3ANetIncome&period=2010-12-31&surface=latest&period_type=duration&start=2010-01-01&unit=USD&dimensions= Input fundies:NetIncome: -10824000 USD (2010-01-01 to 2010-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/911326/000119312513106244/geva-20121231.xml#938554 Filing: 000119312513106244 The citation records this snapshot. The page link may show a newer release later.	−USD 10.55 million Exact value Exact value: -10550000 USD 2010-01-01 – 2010-12-31: -10550000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SYNAGEVA BIOPHARMA CORP · 2010-12-31 SYNAGEVA BIOPHARMA CORP (edgar:911326) Operating Cash Flow: -10550000 USD Concept: fundies:OperatingCashFlow Period: 2010-01-01 to 2010-12-31 Values: Latest reported Published: 2026-11-02T21:30:48Z Snapshot: 2e659e145b62e7937359189eff5497c5180b59e8b9c53cd0c26dcbf8ec576b9f Dimensions: Consolidated View: https://fundies.io/companies/edgar/911326/explain?concept=fundies%3AOperatingCashFlow&period=2010-12-31&surface=latest&period_type=duration&start=2010-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -10550000 USD (2010-01-01 to 2010-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/911326/000119312513106244/geva-20121231.xml#938000 Filing: 000119312513106244 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2011 2011-01-01 – 2011-12-31	−USD 25.31 million Exact value Exact value: -25306000 USD 2011-01-01 – 2011-12-31: -25306000 USD Inspect Net Income Open source Share or cite Citation for Net Income · SYNAGEVA BIOPHARMA CORP · 2011-12-31 SYNAGEVA BIOPHARMA CORP (edgar:911326) Net Income: -25306000 USD Concept: fundies:NetIncome Period: 2011-01-01 to 2011-12-31 Values: Latest reported Published: 2026-11-02T21:30:48Z Snapshot: 2e659e145b62e7937359189eff5497c5180b59e8b9c53cd0c26dcbf8ec576b9f Dimensions: Consolidated View: https://fundies.io/companies/edgar/911326/explain?concept=fundies%3ANetIncome&period=2011-12-31&surface=latest&period_type=duration&start=2011-01-01&unit=USD&dimensions= Input fundies:NetIncome: -25306000 USD (2011-01-01 to 2011-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/911326/000119312514082373/geva-20131231.xml#106242 Filing: 000119312514082373 The citation records this snapshot. The page link may show a newer release later.	−USD 16.59 million Exact value Exact value: -16589000 USD 2011-01-01 – 2011-12-31: -16589000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SYNAGEVA BIOPHARMA CORP · 2011-12-31 SYNAGEVA BIOPHARMA CORP (edgar:911326) Operating Cash Flow: -16589000 USD Concept: fundies:OperatingCashFlow Period: 2011-01-01 to 2011-12-31 Values: Latest reported Published: 2026-11-02T21:30:48Z Snapshot: 2e659e145b62e7937359189eff5497c5180b59e8b9c53cd0c26dcbf8ec576b9f Dimensions: Consolidated View: https://fundies.io/companies/edgar/911326/explain?concept=fundies%3AOperatingCashFlow&period=2011-12-31&surface=latest&period_type=duration&start=2011-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -16589000 USD (2011-01-01 to 2011-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/911326/000119312514082373/geva-20131231.xml#97913 Filing: 000119312514082373 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2012 2012-01-01 – 2012-12-31	−USD 42.95 million Exact value Exact value: -42949000 USD 2012-01-01 – 2012-12-31: -42949000 USD Inspect Net Income Open source Share or cite Citation for Net Income · SYNAGEVA BIOPHARMA CORP · 2012-12-31 SYNAGEVA BIOPHARMA CORP (edgar:911326) Net Income: -42949000 USD Concept: fundies:NetIncome Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T21:30:48Z Snapshot: 2e659e145b62e7937359189eff5497c5180b59e8b9c53cd0c26dcbf8ec576b9f Dimensions: Consolidated View: https://fundies.io/companies/edgar/911326/explain?concept=fundies%3ANetIncome&period=2012-12-31&surface=latest&period_type=duration&start=2012-01-01&unit=USD&dimensions= Input fundies:NetIncome: -42949000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/911326/000119312515065709/geva-20141231.xml#1311168 Filing: 000119312515065709 The citation records this snapshot. The page link may show a newer release later.	−USD 30.94 million Exact value Exact value: -30935000 USD 2012-01-01 – 2012-12-31: -30935000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SYNAGEVA BIOPHARMA CORP · 2012-12-31 SYNAGEVA BIOPHARMA CORP (edgar:911326) Operating Cash Flow: -30935000 USD Concept: fundies:OperatingCashFlow Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T21:30:48Z Snapshot: 2e659e145b62e7937359189eff5497c5180b59e8b9c53cd0c26dcbf8ec576b9f Dimensions: Consolidated View: https://fundies.io/companies/edgar/911326/explain?concept=fundies%3AOperatingCashFlow&period=2012-12-31&surface=latest&period_type=duration&start=2012-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -30935000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/911326/000119312515065709/geva-20141231.xml#1300240 Filing: 000119312515065709 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2013 2013-01-01 – 2013-12-31	−USD 95.45 million Exact value Exact value: -95450000 USD 2013-01-01 – 2013-12-31: -95450000 USD Inspect Net Income Open source Share or cite Citation for Net Income · SYNAGEVA BIOPHARMA CORP · 2013-12-31 SYNAGEVA BIOPHARMA CORP (edgar:911326) Net Income: -95450000 USD Concept: fundies:NetIncome Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T21:30:48Z Snapshot: 2e659e145b62e7937359189eff5497c5180b59e8b9c53cd0c26dcbf8ec576b9f Dimensions: Consolidated View: https://fundies.io/companies/edgar/911326/explain?concept=fundies%3ANetIncome&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=USD&dimensions= Input fundies:NetIncome: -95450000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/911326/000119312515065709/geva-20141231.xml#103924 Filing: 000119312515065709 The citation records this snapshot. The page link may show a newer release later.	−USD 75 million Exact value Exact value: -75002000 USD 2013-01-01 – 2013-12-31: -75002000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SYNAGEVA BIOPHARMA CORP · 2013-12-31 SYNAGEVA BIOPHARMA CORP (edgar:911326) Operating Cash Flow: -75002000 USD Concept: fundies:OperatingCashFlow Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T21:30:48Z Snapshot: 2e659e145b62e7937359189eff5497c5180b59e8b9c53cd0c26dcbf8ec576b9f Dimensions: Consolidated View: https://fundies.io/companies/edgar/911326/explain?concept=fundies%3AOperatingCashFlow&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -75002000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/911326/000119312515065709/geva-20141231.xml#92502 Filing: 000119312515065709 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2014 2014-01-01 – 2014-12-31	−USD 192.65 million Exact value Exact value: -192648000 USD 2014-01-01 – 2014-12-31: -192648000 USD Inspect Net Income Open source Share or cite Citation for Net Income · SYNAGEVA BIOPHARMA CORP · 2014-12-31 SYNAGEVA BIOPHARMA CORP (edgar:911326) Net Income: -192648000 USD Concept: fundies:NetIncome Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T21:30:48Z Snapshot: 2e659e145b62e7937359189eff5497c5180b59e8b9c53cd0c26dcbf8ec576b9f Dimensions: Consolidated View: https://fundies.io/companies/edgar/911326/explain?concept=fundies%3ANetIncome&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:NetIncome: -192648000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/911326/000119312515065709/geva-20141231.xml#1230256 Filing: 000119312515065709 The citation records this snapshot. The page link may show a newer release later.	−USD 150.12 million Exact value Exact value: -150124000 USD 2014-01-01 – 2014-12-31: -150124000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SYNAGEVA BIOPHARMA CORP · 2014-12-31 SYNAGEVA BIOPHARMA CORP (edgar:911326) Operating Cash Flow: -150124000 USD Concept: fundies:OperatingCashFlow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T21:30:48Z Snapshot: 2e659e145b62e7937359189eff5497c5180b59e8b9c53cd0c26dcbf8ec576b9f Dimensions: Consolidated View: https://fundies.io/companies/edgar/911326/explain?concept=fundies%3AOperatingCashFlow&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -150124000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/911326/000119312515065709/geva-20141231.xml#417429 Filing: 000119312515065709 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

94 filings · 1,464 latest values · 1,464 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0000911326, 911326, GEVA, edgar:911326

Also known as SYNAGEVA BIOPHARMA CORP, TRIMERIS INC

SYNAGEVA BIOPHARMA CORP

Latest quarter

Revenue

Operating margin

Operating cash flow

Reported share-count change

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Where revenue goes

2014 2014-01-01 – 2014-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation